 This study evaluates the safety as well as the potential clinical efficacy of an adoptive transfer of CD8 T cells, sorted with HLA-peptide multimers and specific for Melan-A and MELOE-1 melanoma antigens, to patients suffering from advanced metastatic melanoma stages IIIc and IV. 